ReviewiScience2026
Functional diversity of BAI1 (ADGRB1): From angiostasis to synaptic remodeling and disease therapeutics.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-omic Profiling of Recurrence Risk Across Breast Cancer Subtypes.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain-specific angiogenesis inhibitor 1 (BAI1/ADGRB1), a member of the adhesion G protein-coupled receptor (ADGR) family, is regulated at the transcriptional level through epigenetic mechanisms (e.g., MBD2, EZH2, and p53) and alternative promoters, resulting in molecularly distinct isoforms via differential promoters usage (e.g., intron 17-derived variants) and post-translational processing (e.g., matrix metalloproteinase 14 [MMP-14]-mediated Vstat40 release). In cellular and animal studies, both the full-length BAI1 and its proteolytically released extracellular domains have been showed to exhibit multifaceted bioactivity, including inhibition of angiogenesis, suppression of tumor progression, and modulation of immune responses via interactions with CD36, integrins, lipopolysaccharide (LPS), and phosphatidylserine (PtdSer). Furthermore, BAI1 plays crucial roles in neurodevelopmental processes such as synaptic plasticity, neuronal differentiation, and cellular debris clearance, with emerging links to neuropsychiatric disorders. Despite significant advances, critical gaps remain in understanding isoform-specific functions and activation mechanisms across different tissues. This review systematically integrates current knowledge on BAI1, focusing on its genomic regulatory mechanisms, structural isoform diversity, and multidimensional biological functions. It also underscores the need to explore the translational potential of BAI1 in oncology, neurodegenerative diseases, and immune dysregulation, which is essential for advancing our understanding of this complex receptor and its therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.